Abstract:Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAAbstract:Despite the current advances in cancer drug discovery, cancer cells often develop resistance to chemotherapeutic agents leading to poor clinical outcomes. The phenomenon of multidrug resistance (MDR) is prevalent among tumor populations; wherein cancer cells are rendered resistant to structurally and mechanistically unrelated drugs. Of the several factors responsible for the development of MDR, the overexpression of ATP-binding cassette (ABC) efflux transporters poses a serious threat towards attaining a successful chemotherapeutic outcome. The second member of the G sub-family of ABC transporters (ABCG2) is one such efflux transporter that renders the cancer cells resistant to several chemotherapeutic drugs, in turn limiting their intracellular accumulation. The blockade of this efflux pump offers a strategic approach towards increasing the efficiency of chemotherapy. Here we demonstrate the biological activity of a novel N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamide analog, CCTA-1650 that blocks the efflux function of ABCG2 in vitro and in vivo in a preclinical tumor xenograft nude mouse model. Cell cytotoxicity assays performed by combining the chemotherapeutic agents with CCTA-1650 at concentrations of up to 5 μM significantly increased the sensitivity of resistant cancer cells overexpressing both the wild-type and mutant variants of ABCG2. CCTA-1650 inhibits the function of the transporter by decreasing the efflux of substrate chemotherapeutic agents as evident from accumulation and efflux studies with [3H]-mitoxantrone. Furthermore CCTA-1650 at concentrations of up to 5 μM did not affect the expression of ABCG2 transporter upon treatment with CCTA-1650. In addition, CCTA-1650 increased the ATPase activity of ABCG2 in a concentration-dependent manner. CCTA-1650 also displayed inhibition of function of the ABCG2 transporter in an in vivo tumor xenograft nude mouse model. CCTA-1650 at a dose of 30 mg/kg significantly sensitized the resistant tumors to doxorubicin. This effect obtained with combining chemotherapeutic agents with an inhibitor of ABCG2 function both in vitro and in vivo demonstrates the usefulness of CCTA-1650 for the treatment of drug-resistant tumors in the clinic.Citation Format: Atish S. Patel, Tianwen Li, Nagaraju Anreddy, Yufen Zhao, Rishil J. Kathawala, Yijun Wang, Suresh V. Ambudkar, Zhe-Sheng Chen, Changmei Cheng. Design, synthesis and biological evaluation of N-aryl-3,3,3-triﬂuoro-2-hydroxy-2-methylpropionamide analog as a promising inhibitor of the multidrug resistance-linked ABCG2 transporter. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4419. doi:10.1158/1538-7445.AM2015-4419

Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance

Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations

Design, Synthesis and Biological Evaluation of Seco-Dsp/dck Derivatives Reversing P-glycoprotein-mediated Paclitaxel Resistance in A2780/T Cells

Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Exploration of 1,2,3-Triazole-pyrimidine Hybrids As Potent Reversal Agents Against ABCB1-mediated Multidrug Resistance

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators

Design, Synthesis And Biological Evaluation Of N-Aryl-3,3,3-Trifluoro-2-Hydroxy-2-Methylpropionamide Analog As A Promising Inhibitor Of The Multidrug Resistance-Linked Abcg2 Transporter

Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel

New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold

Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance